Serum levels of interleukin (IL)-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality.

[1]  Patrick D. Dummer,et al.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice , 2017, Nature Medicine.

[2]  A. Go,et al.  Inflammation and Progression of CKD: The CRIC Study. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[3]  A. Garg,et al.  Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. , 2015, Journal of the American Society of Nephrology : JASN.

[4]  V. D’Agati,et al.  Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1 , 2014, Kidney international.

[5]  J. Carrero,et al.  The relationship between IL-10 levels and cardiovascular events in patients with CKD. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[6]  Barry I. Freedman,et al.  APOL1 risk variants, race, and progression of chronic kidney disease. , 2013, The New England journal of medicine.

[7]  Keith C. Norris,et al.  Intensive blood-pressure control in hypertensive chronic kidney disease. , 2010, The New England journal of medicine.

[8]  P. Stenvinkel,et al.  IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. , 2005, Kidney international.

[9]  Emil,et al.  Plasma cytokine levels predict mortality in patients with acute renal failure. , 2004, Kidney international.

[10]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.